A method for detecting lupus anticoagulants associated with antiphospholipid syndrome in a patient, comprising: a) detecting a first clotting time of a plasma sample from said patient in a phospholipid-dependent clotting assay measured after the addition of a combination of coagulation inhibitors comprising at least one thrombin inhibitor selected from the group consisting of d-phenylalanyl-1-prolyl-1-arginine-chloromethyl ketone (PPACK), I-2581, hirudin, hirudin derivatives, lepirudin, desirudin, hirudin analogues, biva!irudin, argatroban, melagatran, dabigatran, and combinations thereof or at least one factor Xa inhibitor selected from the group consisting of rivaroxaban, apixaban, edoxaban, betrixaban, antistasin, Tick Anticoagulant Protein (TAP), and combinations thereof and the addition of 0.002 g/l to 0.2 g/l of phospholipid to the patient sample; b) detecting a second clotting time of the plasma sample in the phospholipid-dependent clotting assay measured after the addition of the combination of coagulation inhibitors of step a), and the addition of 0.2 g/l to 5.0 g/l phospholipid to the patient sample; wherein each of the phospholipid-dependent clotting assays of step a) and step b) further comprise diluting said patient plasma sample with normal pooled plasma; and c) determining a patient ratio which is the ratio of the first to the second clotting times of the patient plasma and comparing the patient ratio to a cutoff ratio normalized to a suitable reference value established from normal, healthy subjects; wherein the patient ratio determined in step c) being greater than the cutoff ratio is indicative of the presence of lupus anticoagulants in the test plasma. a) detecting a first clotting time of a plasma sample from said patient in a phospholipid-dependent clotting assay measured after the addition of a combination of coagulation inhibitors comprising at least one thrombin inhibitor selected from the group consisting of d-phenylalanyl-1-prolyl-1-arginine-chloromethyl ketone (PPACK), I-2581, hirudin, hirudin derivatives, lepirudin, desirudin, hirudin analogues, biva!irudin, argatroban, melagatran, dabigatran, and combinations thereof or at least one factor Xa inhibitor selected from the group consisting of rivaroxaban, apixaban, edoxaban, betrixaban, antistasin, Tick Anticoagulant Protein (TAP), and combinations thereof and the addition of 0.002 g/l to 0.2 g/l of phospholipid to the patient sample; b) detecting a second clotting time of the plasma sample in the phospholipid-dependent clotting assay measured after the addition of the combination of coagulation inhibitors of step a), and the addition of 0.2 g/l to 5.0 g/l phospholipid to the patient sample; wherein each of the phospholipid-dependent clotting assays of step a) and step b) further comprise diluting said patient plasma sample with normal pooled plasma; and c) determining a patient ratio which is the ratio of the first to the second clotting times of the patient plasma and comparing the patient ratio to a cutoff ratio normalized to a suitable reference value established from normal, healthy subjects; wherein the patient ratio determined in step c) being greater than the cutoff ratio is indicative of the presence of lupus anticoagulants in the test plasma. <EOS>